(VIANEWS) – RYANAIR HOLD. PLC (RYA.IR), NAVAMEDIC (NAVA.OL), ITERA (ITERA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RYANAIR HOLD. PLC (RYA.IR)
38.7% sales growth and 28.95% return on equity
Ryanair Holdings plc, together with its subsidiaries, provides scheduled-passenger airline services in Ireland, the United Kingdom, Italy, Spain, and internationally. It is also involved in the provision of various ancillary services, such as non-flight scheduled and Internet-related services, as well as in-flight sale of beverages, food, duty-free, and merchandise; and markets car hire, travel insurance, and accommodation services through its website and mobile app. In addition, the company offers aircraft and passenger handling, ticketing, and maintenance and repair services; and markets car parking, fast-track, airport transfers, attractions, and activities on its website and mobile app, as well as sells gift vouchers. Ryanair Holdings plc was incorporated in 1996 and is headquartered in Swords, Ireland.
Earnings Per Share
As for profitability, RYANAIR HOLD. PLC has a trailing twelve months EPS of €1.17.
PE Ratio
RYANAIR HOLD. PLC has a trailing twelve months price to earnings ratio of 13.96. Meaning, the purchaser of the share is investing €13.96 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.95%.
Volume
Today’s last reported volume for RYANAIR HOLD. PLC is 119577 which is 90.69% below its average volume of 1285520.
More news about RYANAIR HOLD. PLC.
2. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.46. Meaning, the purchaser of the share is investing kr32.46 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 454.46M for the twelve trailing months.
Volume
Today’s last reported volume for NAVAMEDIC is 143419 which is 235.4% above its average volume of 42760.
Moving Average
NAVAMEDIC’s worth is above its 50-day moving average of kr35.09 and higher than its 200-day moving average of kr36.27.
Sales Growth
NAVAMEDIC’s sales growth is 22.8% for the current quarter and 17.3% for the next.
More news about NAVAMEDIC.
3. ITERA (ITERA.OL)
12.4% sales growth and 97.07% return on equity
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.79.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 15.76. Meaning, the purchaser of the share is investing kr15.76 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 97.07%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ITERA’s EBITDA is 1.29.
Yearly Top and Bottom Value
ITERA’s stock is valued at kr12.45 at 07:20 EST, way under its 52-week high of kr16.50 and way higher than its 52-week low of kr10.95.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 831.86M for the twelve trailing months.
More news about ITERA.
4. SCHLUMBERGER (SLB.PA)
11.6% sales growth and 22.45% return on equity
Schlumberger Limited engages in the provision of technology for the energy industry worldwide. The company operates through four divisions: Digital & Integration, Reservoir Performance, Well Construction, and Production Systems. The company provides field development and hydrocarbon production, carbon management, integration of adjacent energy systems; reservoir interpretation and data processing services for exploration data; and well construction and production improvement services and products. It also offers subsurface geology and fluids evaluation information; open and cased hole services; exploration and production pressure, and flow-rate measurement services; and pressure pumping, well stimulation, and coiled tubing equipment solutions. In addition, the company offers mud logging, directional drilling, measurement-while-drilling, and logging-while-drilling services, as well as engineering support services; supplies drilling fluid systems; designs, manufactures, and markets roller cone and fixed cutter drill bits; bottom-hole-assembly and borehole enlargement technologies; well cementing products and services; well planning, well drilling, engineering, supervision, logistics, procurement, and contracting of third parties, as well as drilling rig management solutions; and drilling equipment and services, as well as land drilling rigs and related services. Further, it provides artificial lift production equipment and optimization services; supplies packers, safety valves, sand control technology, and various intelligent well completions technology and equipment; designs and manufactures valves, chokes, actuators, and surface trees; and OneSubsea an integrated solutions, products, systems, and services, including wellheads, subsea trees, manifolds and flowline connectors, control systems, connectors, and services. The company was formerly known as Socie´te´ de Prospection E´lectrique. Schlumberger Limited was founded in 1926 and is based in Houston, Texas.
Earnings Per Share
As for profitability, SCHLUMBERGER has a trailing twelve months EPS of €2.53.
PE Ratio
SCHLUMBERGER has a trailing twelve months price to earnings ratio of 21.02. Meaning, the purchaser of the share is investing €21.02 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.45%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 23.7% and 22.7%, respectively.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Sep 5, 2023, the estimated forward annual dividend rate is 0.93 and the estimated forward annual dividend yield is 1.62%.
More news about SCHLUMBERGER.
5. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.33.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 69.7. Meaning, the purchaser of the share is investing kr69.7 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
Moving Average
VISTIN PHARMA’s value is higher than its 50-day moving average of kr22.73 and way above its 200-day moving average of kr19.49.
Volume
Today’s last reported volume for VISTIN PHARMA is 4012 which is 86.43% below its average volume of 29581.
Revenue Growth
Year-on-year quarterly revenue growth grew by 54.7%, now sitting on 410.31M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 2.36.
More news about VISTIN PHARMA.
